JPH10506609A - 創傷治癒過程の減衰 - Google Patents
創傷治癒過程の減衰Info
- Publication number
- JPH10506609A JPH10506609A JP8504443A JP50444396A JPH10506609A JP H10506609 A JPH10506609 A JP H10506609A JP 8504443 A JP8504443 A JP 8504443A JP 50444396 A JP50444396 A JP 50444396A JP H10506609 A JPH10506609 A JP H10506609A
- Authority
- JP
- Japan
- Prior art keywords
- heparinase
- enzyme
- cells
- cell
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.Flavobacterium heparinum由来のヘパリナーゼ1、Flavobacterium heparin um由来のヘパリナーゼ2、Flavobacterium heparinum由来のヘパリナーゼ3、Fl avobacterium heparinum由来のコンドロイチナーゼACおよびFlavobacterium hep arinum由来のコンドロイチナーゼB、Bacteroides菌株由来のヘパリナーゼ、Flav obacterium Hp206由来のヘパリナーゼ、Cytophagia種由来のヘパリナーゼ、Bact eroides種由来のコンドロイチン硫酸分解酵素、Proteus vulgaris由来のコンド ロイチン硫酸分解酵素、Microcossus由来のコンドロイチン硫酸分解酵素、Vibri o種由来のコンドロイチン硫酸分解酵素、Arthrobacter aurescens由来のコンド ロイチン硫酸分解酵素、ここでこれらの酵素は細菌において発現される組換えヌ クレオチド配列から発現され、ならびにこれらの組み合わせからなる群から選択 されるグリコサミノグリカン分解酵素を、有効量の該酵素の局在化投与のための 薬学的に許容可能なキャリアとの組み合わせで含む薬学的組成物であって、該組 成物は、細胞外基質からヘパリン結合成長因子および分子を放出し、細胞表面レ セプターからコンドロイチン硫酸を除去し、そしてその成長因子レセプター複合 体からヘパラン硫酸成分を除去することにより、正常な創傷治癒を増強する、組 成物。 2.前記キャリアが、局部投与のための薬学的に許容可能なキャリアである、請 求項1に記載の組成物。 3.前記キャリアが、軟膏剤、ポリマー性フィルム、ゲル、微粒子、マイクロカ プセル、リポソーム、プロテオソーム、リポスフェア、インプラント、経皮パッ チおよび包帯からなる群から選択される、請求項2に記載の組成物。 4.前記酵素が、ポリマー性基質に取り込まれている、請求項3に記載の組成物 。 5.正常な創傷治癒を増強するためのシステムであって、 Flavobacterium heparinum由来のヘパリナーゼ1、Flavobacterium heparinum 由来のヘパリナーゼ2、Flavobacterium heparinum由来のヘパリナーゼ3、Flav obacterium heparinum由来のコンドロイチナーゼAC、Flavobacterium heparinum 由来のコンドロイチナーゼB、Bacteroides菌株由来のヘパリナーゼ、Flavobacte rium Hp206由来のヘパリナーゼ、Cytophagia種由来のヘパリナーゼ、Bacteroide s種由来のコンドロイチン硫酸分解酵素、Proteus vulgaris由来のコンドロイチ ン硫酸分解酵素、Microcossus由来のコンドロイチン硫酸分解酵素、Vibrio種由 来のコンドロイチン硫酸分解酵素、Arthrobacter aurescens由来のコンドロイチ ン硫酸分解酵素、ここでこれらの酵素は細菌において発現される組換えヌクレオ チド配列から発現され、ならびにこれらの組み合わせからなる群から選択され、 薬学的に許容可能なキャリアと組み合わせられる、グリコサミノグリカン分解酵 素と、 細胞外基質からヘパリン結合成長因子および分子を放出し、細胞表面レセプタ ーからコンドロイチン硫酸を除去し、そしてその成長因子レセプター複合体から ヘパラン硫酸成分を除去することにより、正常な創傷治癒を増強するのに有効な 投薬量で、キャリアと組み合わせて酵素を送達するための装置と、 を含む、システム。 6.前記送達手段がカテーテルまたは内視鏡である、請求項5に記載のシステム 。 7.前記グリコサミノグリカン分解酵素が融合タンパク質である、請求項1に記 載の組成物。 8.前記グリコサミノグリカン分解酵素が、標的細胞の特定の分子と結合する、 タンパク質、多糖類、核酸および脂質からなる群から選択される標的分子に融合 される、請求項7に記載の組成物。 9.前記分子が、細胞表面分子と結合する、ホルモン、抗体、インテグリンおよ び細胞外基質結合分子からなる群から選択される、請求項8に記載の組成物。 10.前記酵素が、該酵素が天然に存在しない生物において、組換えヌクレオチ ド配列から発現され、そして該酵素が、該酵素が天然に存在しない該生物におい て、異なる形でプロセスされる、請求項1に記載の組成物。 11.細胞外基質からヘパリン結合成長因子および分子を放出し、細胞表面レセ プターからコンドロイチン硫酸を除去し、そしてその成長因子レセプター複合体 からヘパラン硫酸成分を除去することにより、正常な創傷治癒を増強する際にお ける、請求項1から10に記載の組成物またはシステムの使用。 12.前記組成物が、再狭窄を防止することによって血管の正常な創傷治癒を増 強する、請求項11に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US273,109 | 1994-07-08 | ||
US08/273,109 US5997863A (en) | 1994-07-08 | 1994-07-08 | Attenuation of wound healing processes |
PCT/US1995/008608 WO1996001648A1 (en) | 1994-07-08 | 1995-07-07 | Attenuation of wound healing processes |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10506609A true JPH10506609A (ja) | 1998-06-30 |
JP4152433B2 JP4152433B2 (ja) | 2008-09-17 |
Family
ID=23042598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50444396A Expired - Fee Related JP4152433B2 (ja) | 1994-07-08 | 1995-07-07 | 創傷治癒過程の減衰 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5997863A (ja) |
EP (1) | EP0769961B1 (ja) |
JP (1) | JP4152433B2 (ja) |
AT (1) | ATE344051T1 (ja) |
AU (1) | AU707007B2 (ja) |
CA (1) | CA2194370C (ja) |
DE (1) | DE69535282T2 (ja) |
ES (1) | ES2279514T3 (ja) |
WO (1) | WO1996001648A1 (ja) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3713276B2 (ja) * | 1995-09-29 | 2005-11-09 | バイオマリン ファーマシューティカル インコーポレイテッド | 炎症反応の軽減のためのヘパリナーゼの使用 |
WO1997016556A1 (en) | 1995-10-30 | 1997-05-09 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from heparinase i |
GB2317182B (en) * | 1996-09-11 | 2000-11-01 | Johnson & Johnson Medical | Sulfated polysaccharides and uses thereof in medical treatment |
US6699672B1 (en) * | 1997-09-02 | 2004-03-02 | Insight Biopharmaceuticals Ltd. | Heparanase specific molecular probes and their use research and medical applications |
US20040213789A1 (en) * | 1997-09-02 | 2004-10-28 | Oron Yacoby-Zeevi | Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies |
US20030161823A1 (en) * | 1998-08-31 | 2003-08-28 | Neta Ilan | Therapeutic and cosmetic uses of heparanases |
US20020088019A1 (en) * | 1997-09-02 | 2002-07-04 | Oron Yacoby-Zeevi | Methods of and pharmaceutical compositions for improving implantation of embryos |
US6177545B1 (en) * | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
US20010006630A1 (en) * | 1997-09-02 | 2001-07-05 | Oron Yacoby-Zeevi | Introducing a biological material into a patient |
WO1999046368A2 (en) * | 1998-03-13 | 1999-09-16 | Biomarin Pharmaceuticals | Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment |
US7056504B1 (en) | 1998-08-27 | 2006-06-06 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase I and II |
WO2000012726A2 (en) | 1998-08-27 | 2000-03-09 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase i and ii |
US20030217375A1 (en) * | 1998-08-31 | 2003-11-20 | Eyal Zcharia | Transgenic animals expressing heparanase and uses thereof |
EP1157118A4 (en) * | 1999-03-01 | 2002-07-17 | Insight Strategy & Marketing | POLYNUCLEOTID ENCODING A POLYPEPTIDE WITH HEPARANASE ACTIVITY AND ITS EXPRESSION IN GENETICALLY MODIFIED CELLS |
CA2370539C (en) * | 1999-04-23 | 2009-01-06 | Massachusetts Institute Of Technology | System and method for notating polymers |
US6979563B1 (en) | 1999-11-17 | 2005-12-27 | Biomarin Enzymes, Inc. | Attenuation of tumor growth, metastasis and angiogenesis |
CA2414185A1 (en) * | 1999-11-17 | 2001-05-25 | Ibex Technologies, Inc. | Attenuation of tumor growth, metastasis and angiogenesis by use of chondroitin sulfate degrading enzymes |
WO2001038399A1 (fr) * | 1999-11-24 | 2001-05-31 | Seikagaku Corporation | Procede de traitement des maladies des tissus superficiels |
ES2527853T3 (es) * | 2000-03-08 | 2015-01-30 | Massachusetts Institute Of Technology | Heparinasa III y sus usos |
US7083937B2 (en) | 2000-09-12 | 2006-08-01 | Massachusetts Institute Of Technology | Methods and products related to the analysis of polysaccarides |
CA2423469A1 (en) | 2000-10-18 | 2002-04-25 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
WO2002091999A2 (en) * | 2001-05-09 | 2002-11-21 | Geron Corporation | Treatment for wounds |
IL160188A0 (en) * | 2001-08-13 | 2004-07-25 | Univ Florida | Materials and methods to promote repair of nerve tissue |
US6671189B2 (en) * | 2001-11-09 | 2003-12-30 | Minebea Co., Ltd. | Power converter having primary and secondary side switches |
GB0205022D0 (en) | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
US6974592B2 (en) * | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
WO2004108069A2 (en) * | 2002-05-04 | 2004-12-16 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US6962699B2 (en) | 2002-06-03 | 2005-11-08 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase B |
US20060153827A1 (en) * | 2002-08-15 | 2006-07-13 | Gruskin Elliott A | Chimeric protein |
KR101175774B1 (ko) * | 2002-11-04 | 2012-08-21 | 오션 뉴트리션 캐나다 리미티드 | 다중 쉘을 갖는 마이크로캡슐 및 이의 제조 방법 |
EP2460881B1 (en) | 2003-05-16 | 2017-05-03 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of CNS |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
ATE524067T1 (de) | 2003-05-16 | 2011-09-15 | Acorda Therapeutics Inc | Zusammensetzungen und verfahren zur behandlung von zns-schäden |
US20060269552A1 (en) * | 2003-06-09 | 2006-11-30 | Oron Yacoby-Zeevi | Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies |
WO2005074655A2 (en) * | 2004-01-30 | 2005-08-18 | Emory University | Materials and method for promotion of nerve regeneration |
EP1737954A2 (en) * | 2004-03-10 | 2007-01-03 | The Massachusetts Institute Of Technology | Recombinant chondroitinase abc i and uses thereof |
WO2005112986A2 (en) * | 2004-05-18 | 2005-12-01 | Acorda Therapeutics, Inc. | Purifying chondroitinase and stable formulations thereof |
US8034450B2 (en) * | 2005-01-21 | 2011-10-11 | Ocean Nutrition Canada Limited | Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof |
US9968120B2 (en) | 2006-05-17 | 2018-05-15 | Dsm Nutritional Products Ag | Homogenized formulations containing microcapsules and methods of making and using thereof |
JP5189985B2 (ja) * | 2005-09-26 | 2013-04-24 | アコーダ セラピューティクス、インク. | コンドロイチナーゼabci変異体を用いた組成物およびその使用方法 |
WO2007049361A1 (ja) * | 2005-10-27 | 2007-05-03 | Stelic Corp. | 肝線維化抑制剤 |
US7767420B2 (en) * | 2005-11-03 | 2010-08-03 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
US7691613B2 (en) * | 2006-11-03 | 2010-04-06 | Momenta Pharmaceuticals, Inc. | Glycosaminoglycan lyase IV and uses thereof |
US7691612B2 (en) | 2005-11-03 | 2010-04-06 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
JP2009533490A (ja) * | 2006-04-07 | 2009-09-17 | オーシャン ニュートリッション カナダ リミテッド | 低い界面張力を有する物質を含む乳濁液およびマイクロカプセル、ならびにそれらを作製および使用する方法 |
NZ596403A (en) * | 2006-06-05 | 2013-02-22 | Ocean Nutrition Canada Ltd | Microcapsules with improved shells with wax in the outer shell |
ES2473610T3 (es) | 2006-10-10 | 2014-07-07 | Acorda Therapeutics, Inc. | Composiciones y métodos de uso de mutantes de condroitinasa ABCI |
CN101641087B (zh) | 2007-01-10 | 2013-08-21 | 加拿大海洋营养食品有限公司 | 素食的微胶囊 |
US20090286289A1 (en) * | 2008-03-10 | 2009-11-19 | Pang Danny Z | Production of Hyaluronate Unsaturated Disaccharides and its Application |
EP2756849B1 (en) * | 2011-09-15 | 2016-03-16 | Seikagaku Corporation | Skeletal muscle regeneration promoter |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
CN109182321A (zh) * | 2018-09-14 | 2019-01-11 | 深圳市长征生物科技有限公司 | 肝素黄杆菌肝素酶ⅰ的高效制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4760131A (en) * | 1986-04-23 | 1988-07-26 | Collagen Corporation | Wound-healing composition |
US5169772A (en) * | 1988-06-06 | 1992-12-08 | Massachusetts Institute Of Technology | Large scale method for purification of high purity heparinase from flavobacterium heparinum |
WO1990006590A1 (en) * | 1988-12-01 | 1990-06-14 | Edward Bok | Improved installation for transport and processing under a pulsating double-floating condition |
US5116615A (en) * | 1989-01-27 | 1992-05-26 | Immunolytics, Inc. | Method for treating benign prostatic hypertrophy |
KR927003090A (ko) * | 1989-08-23 | 1992-12-17 | 하다사 메디칼 오르가니제이션 | 헤파린효소를 포함하는 상처 치유 약제 |
US5242810A (en) * | 1990-12-07 | 1993-09-07 | Biogen, Inc. | Bifunctional inhibitors of thrombin and platelet activation |
US5262325A (en) * | 1991-04-04 | 1993-11-16 | Ibex Technologies, Inc. | Method for the enzymatic neutralization of heparin |
US5389539A (en) * | 1992-11-30 | 1995-02-14 | Massachusetts Institute Of Technology | Purification of heparinase I, II, and III from Flavobacterium heparinum |
AU1176595A (en) * | 1993-11-12 | 1995-05-29 | International Technology Management Associates, Ltd. | Methods of repairing connective tissues |
EP0726773A1 (en) * | 1993-11-17 | 1996-08-21 | Massachusetts Institute Of Technology | Method for inhibiting angiogenesis using heparinase |
-
1994
- 1994-07-08 US US08/273,109 patent/US5997863A/en not_active Expired - Fee Related
-
1995
- 1995-07-07 CA CA002194370A patent/CA2194370C/en not_active Expired - Fee Related
- 1995-07-07 ES ES95926645T patent/ES2279514T3/es not_active Expired - Lifetime
- 1995-07-07 AT AT95926645T patent/ATE344051T1/de not_active IP Right Cessation
- 1995-07-07 EP EP95926645A patent/EP0769961B1/en not_active Expired - Lifetime
- 1995-07-07 DE DE69535282T patent/DE69535282T2/de not_active Expired - Fee Related
- 1995-07-07 AU AU30949/95A patent/AU707007B2/en not_active Ceased
- 1995-07-07 JP JP50444396A patent/JP4152433B2/ja not_active Expired - Fee Related
- 1995-07-07 WO PCT/US1995/008608 patent/WO1996001648A1/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
US5997863A (en) | 1999-12-07 |
WO1996001648A1 (en) | 1996-01-25 |
AU3094995A (en) | 1996-02-09 |
DE69535282D1 (de) | 2006-12-14 |
ATE344051T1 (de) | 2006-11-15 |
ES2279514T3 (es) | 2007-08-16 |
EP0769961A1 (en) | 1997-05-02 |
CA2194370C (en) | 2001-02-27 |
EP0769961B1 (en) | 2006-11-02 |
CA2194370A1 (en) | 1996-01-25 |
JP4152433B2 (ja) | 2008-09-17 |
AU707007B2 (en) | 1999-07-01 |
DE69535282T2 (de) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4152433B2 (ja) | 創傷治癒過程の減衰 | |
US7264799B2 (en) | Use of heparinases to decrease inflammatory response | |
AU761592B2 (en) | Introducing a biological material into a patient | |
EP0487627B1 (en) | Wound healing preparations containing heparanase | |
Whaley et al. | C2 synthesis by human monocytes is modulated by a nicotinic cholinergic receptor | |
US20200016247A1 (en) | Compositions and methods for the treatment of cns injuries | |
US20070141101A1 (en) | Method for stimulating angiogenesis and wound healing | |
JPH09508892A (ja) | ヘパリナーゼを用いる血管形成の阻害方法 | |
AU2003242497B2 (en) | Method and Pharmaceutical Composition Utilising Heparanase | |
JP2000136148A (ja) | 細胞への付着阻害組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070717 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20071012 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071017 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080610 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080702 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110711 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |